Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial.
Fumagalli RM, Voci D, Bikdeli B, Bingisser R, Colucci G, Forgo G, Gerardi T, Gerber B, Grigorean A, Klok FA, Righini M, Robert-Ebadi H, Stortecky S, Ulrich S, Wolf S, Wyss D, Hobohm L, Kucher N, Barco S; OVID investigators. Fumagalli RM, et al. Res Pract Thromb Haemost. 2024 Jul 26;8(5):102534. doi: 10.1016/j.rpth.2024.102534. eCollection 2024 Jul. Res Pract Thromb Haemost. 2024. PMID: 39252826 Free PMC article.
Nosocomial COVID-19 Incidence and Secondary Attack Rates among Patients of Tertiary Care Center, Zurich, Switzerland.
Wolfensberger A, Kufner V, Zaheri M, Zeeb M, Nortes I, Schreiber PW, Vazquez M, Schärer V, Scheier T, Schmutz S, Probst E, Saleschus D, Huber M, Rampini SK, Zingg W. Wolfensberger A, et al. Among authors: probst e. Emerg Infect Dis. 2022 Oct;28(10):2087-2090. doi: 10.3201/eid2810.220321. Epub 2022 Sep 1. Emerg Infect Dis. 2022. PMID: 36048771 Free PMC article.
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Barco S, Voci D, Held U, Sebastian T, Bingisser R, Colucci G, Duerschmied D, Frenk A, Gerber B, Götschi A, Konstantinides SV, Mach F, Robert-Ebadi H, Rosemann T, Simon NR, Spechbach H, Spirk D, Stortecky S, Vaisnora L, Righini M, Kucher N; OVID investigators. Barco S, et al. Lancet Haematol. 2022 Aug;9(8):e585-e593. doi: 10.1016/S2352-3026(22)00175-2. Epub 2022 Jun 30. Lancet Haematol. 2022. PMID: 35779558 Free PMC article. Clinical Trial.
Major adverse limb events in patients with femoro-popliteal and below-the-knee peripheral arterial disease treated with either sirolimus-coated balloon or standard uncoated balloon angioplasty: a structured protocol summary of the "SirPAD" randomized controlled trial.
Barco S, Sebastian T, Voci D, Engelberger RP, Grigorean A, Holy E, Leeger C, Münger M, Périard D, Probst E, Spescha R, Held U, Kucher N. Barco S, et al. Among authors: probst e. Trials. 2022 Apr 21;23(1):334. doi: 10.1186/s13063-022-06242-8. Trials. 2022. PMID: 35449070 Free PMC article.
49 results